Literature DB >> 21073951

Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: Implication of DNA binding and acetylation of the receptor.

Naoki Harada1, Kiyotaka Atarashi, Yohei Murata, Ryoichi Yamaji, Yoshihisa Nakano, Hiroshi Inui.   

Abstract

Androgen receptor (AR) is a ligand-dependent transcription factor and plays a key role in the development of prostate cancer. Resveratrol, a polyphenolic compound, inhibits AR function and reduces the level of prostate-specific antigen (PSA), a notable target gene of AR. Here, we investigated the mechanisms by which resveratrol inhibits AR function. Although the protein levels of AR were decreased by resveratrol treatment for 24h, the decrease could not fully account for the suppression of AR function. The total and the nuclear AR levels were not affected after incubation with 10μM resveratrol for 3h, whereas resveratrol inhibited the binding of AR to the enhancer region of PSA and decreased the acetylation of AR even at this early phase. Inhibition of transcription by resveratrol was weaker in the AR acetylation site mutant than in the wild-type. In later phase (24h) after incubation with resveratrol, the ligand-induced nuclear accumulation of AR was markedly decreased by resveratrol. These data show that resveratrol inhibits DNA binding of AR, presumably by decreasing its level of acetylation and suggest that acetylation of AR is involved in its accumulation in the nucleus.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21073951     DOI: 10.1016/j.jsbmb.2010.11.002

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

1.  Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells.

Authors:  Naoki Harada; Kaoru Inoue; Ryoichi Yamaji; Yoshihisa Nakano; Hiroshi Inui
Journal:  Cancer Sci       Date:  2012-04-11       Impact factor: 6.716

Review 2.  Nanoformulation of natural products for prevention and therapy of prostate cancer.

Authors:  Vanna Sanna; Imtiaz A Siddiqui; Mario Sechi; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2012-11-29       Impact factor: 8.679

3.  Molecular insight into the differential anti-androgenic activity of resveratrol and its natural analogs: in silico approach to understand biological actions.

Authors:  Sandipan Chakraborty; Avinash Kumar; Nasir A Butt; Liangfen Zhang; Raquema Williams; Agnes M Rimando; Pradip K Biswas; Anait S Levenson
Journal:  Mol Biosyst       Date:  2016-05

4.  Resveratrol Inhibits IL-6-Induced Transcriptional Activity of AR and STAT3 in Human Prostate Cancer LNCaP-FGC Cells.

Authors:  Mee-Hyun Lee; Joydeb Kumar Kundu; Young-Sam Keum; Yong-Yeon Cho; Young-Joon Surh; Bu Young Choi
Journal:  Biomol Ther (Seoul)       Date:  2014-09-30       Impact factor: 4.634

5.  Androgen receptor as potential therapeutic target in metastatic endometrial cancer.

Authors:  Ingvild Løberg Tangen; Therese Bredholt Onyango; Reidun Kopperud; Anna Berg; Mari K Halle; Anne M Øyan; Henrica M J Werner; Jone Trovik; Karl Henning Kalland; Helga B Salvesen; Camilla Krakstad
Journal:  Oncotarget       Date:  2016-08-02

Review 6.  Integrin αvβ3 in the Mediating Effects of Dihydrotestosterone and Resveratrol on Breast Cancer Cell Proliferation.

Authors:  Yih Ho; Zi-Lin Li; Ya-Jung Shih; Yi-Ru Chen; Kuan Wang; Jacqueline Whang-Peng; Hung-Yun Lin; Paul J Davis
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

7.  Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cells.

Authors:  Wolfgang Streicher; Manuel Luedeke; Anca Azoitei; Friedemann Zengerling; Alexander Herweg; Felicitas Genze; Mark G Schrader; Andres J Schrader; Marcus V Cronauer
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.